These results can guide your treatment options, including newer medications like Imcivree
A review of PubMed, EMBASE and Cochrane from inception through October 2024 yielded three studies from Denmark, Switzerland and the United States comprising 410 patients, including 207 who received GLP-1 receptor agonists
Neural Pathways and Weight Loss: Semaglutide modulates food preference, reduces food intake, and causes weight loss without decreasing energy expenditure by interacting with the brain through several pathways involved in food intake and energy expenditure (Gabery et al., 2020)
For both Most Studied Pathways and Gene-Associated Pathways, the threshold of rank 30 was chosen to balance sensitivity and specificity, capturing pathways with substantial evidence while minimizing the inclusion of less relevant ones
The study showed an average weight loss of roughly 19% for those taking the lower, 4 mg dose
(Clearly, this is not an exact science.) However, not all GLP-1s come in auto-injector pens